Goldman Sachs Maintains Buy on Pfizer (PFE)

Goldman Sachs is out with its report today on Pfizer PFE, maintaining Buy. In a note to clients, Goldman Sachs writes, "We remain confident that PFE's Ian Read will move rapidly to pare the business through break-ups/spins, and expect more granularity with respect to timing on the call. While we continue to advocate a full break up (SOTP of $25), we think the 'generics' business, which we estimate is worth ($8/share) may not yet be ready to stand alone until ANDA capabilities are acquired." Goldman Sachs has a $22 PT on PFE. At the time of posting, shares of PFE were trading pre-market at $20.47, up 0.05% from Friday's close.